Originally published on 12/19/25

President Donald Trump recently announced a 100 percent tariff on some President Donald Trump has just announced that nine new pharmaceutical companies— Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Roche’s Genentech unit, Gilead, GSK, Merck, Novartis and Sanofi—will soon be joining TrumpRx, a federal direct-to-consumer marketplace designed to lower prescription costs by allowing Americans to buy medications at discounted “cash prices” directly from manufacturers via TrumpRx.gov. 

This news comes just over a month after President Trump and his administration first unveiled the new initiative, which began with a partnership withPfizer, the pharmaceutical giant known for its COVID-19 vaccine, Novo Nordisk and Eli Lilly, companies best known for their GLP-1’s Wegovy and Zepbound, respectively. Below, we break down everything you need to know about TrumpRx, including which new drugs are being added to the list come 2026.

What to know about TrumpRx 

TrumpRx will be a direct-to-consumer sales program where Americans can purchase medicines at a discounted rate. These savings can go as high as 85%, but the average discount will be 50%. 

“The United States is done subsidizing the healthcare of the rest of the world,” the 45th and 47th President of the United States said in a news conference. “By taking this bold step, we’re ending the era of global price gouging at the expense of American families.”

At the time of the announcement, Trump also revealed that TrumpRx would be partnering with Pfizer to help make these medications more accessible to Americans. This partnership follows an earlier agreement to offer drugs to Medicaid programs at most-favored-nation (MFN) prices—the same lower rates paid by patients in other developed countries, which are significantly below average market prices in the U.S.

“The agreement will provide every State Medicaid program in the country access to MFN drug prices on Pfizer products, resulting in many millions of dollars in savings and continuing President Trump’s historic efforts to strengthen the program for the most vulnerable,” reads a press release issued by the White House. “The agreement ensures foreign nations can no longer use price controls to freeride on American innovation by guaranteeing MFN prices on all new innovative medicines Pfizer brings to market.” 

Several of these drugs will be available on the TrumpRx site once it launches, which Pfizer hopes will allow Americans to get the medicines they need at a much more attainable price. 

“By working closely with the Administration, we are lowering costs for patients and enabling greater investment in the U.S. biopharmaceutical ecosystem by ending the days when American families alone carried the global burden of paying for innovation. This is about putting all patients first and ensuring America remains the world’s leading engine of medical breakthroughs,” he continued. “We now have the certainty and stability we need on two critical fronts, tariffs and pricing, that have suppressed the industry’s valuations to historic lows.” 

A look at the weight loss drugs expected to be sold on TrumpRx

Along with Pfizer, President Trump announced on Thursday, November 6, that TrumpRx would be working with Novo Nordisk—which created Wegovy—and Eli Lilly—which created Zepbound— to help lower the costs of GLP-1s. Under this deal, the highly sought-after weight loss drugs will cost around $50 to $350 a month, depending on people’s insurance coverage and what dosage they want. 

Currently, the two drugs cost around $1,000 a month out of pocket, but again, that price can vary based on insurance, dosage and where the consumer purchases it, meaning that once TrumpRx launches in 2026, Americans could save up to $950 on their GLP-1s. 

“The agreement represents a historic reduction in prices for Americans on the two drugs with the highest annual expenditures in the United States,” the White House said in a statement. 

 President Trump announced that a select group of people on Medicare and Medicaid will be able to access these GLP-1 medications for $245 a month. However, Medicare beneficiaries will pay just $50 per month for the weight loss drugs—a significant departure from standard Medicare and Medicaid coverage, which typically only covers GLP-1s for the treatment of Type 2 diabetes.

“These low prices will enable Medicare to cover Wegovy and Zepbound for patients with obesity and related comorbidities for the first time,” the White House said in that same statement. “The agreement also provides that Eli Lilly and Novo Nordisk will guarantee MFN prices on all new medicines that they bring to market, repatriate increased foreign revenue on existing products, and provide every State Medicaid program in the country access to MFN drug prices on their products.” 

As of publication, it’s unclear who exactly on Medicare and Medicaid will qualify for the discounted weight loss drug once TrumpRx launches. It’s also unclear what drugs, aside from GLP-1s, it will be selling. 

What new drugs are joining TrumpRx

The most recent TrumpRX news came on Friday, December 19, when the 45th and 47th U.S. president announced that Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Roche’s Genentech unit, Gilead, GSK, Merck, Novartis and Sanofi would all be joining the site. 

According to the White House, by adding these companies, Americans can see reduced prices on “drugs that treat numerous costly and chronic conditions, including type two diabetes, rheumatoid arthritis, multiple sclerosis, asthma, chronic obstructive pulmonary disease (COPD), hepatitis B and C, human immunodeficiency virus (HIV) and certain cancers.” 

This includes: 

• Amgen’s cholesterol-lowering drug Repatha, which promises to go from $573 to $239 on TrumpRx. 
• Bristol Myers Squibb’s HIV medication Reyataz, going from $1,449 to $217 on TrumpRX. 
• Boehringer Ingelheim’s type 2 diabetes medication Jentadueto, which goes from $525 to $55 on TrumpRx.
• Genentech’s flu medication Xofluza, from $168 to $50 on TrumpRx. 
• Gilead Sciences’ Hepatitis C medication Epclusa, from $24,920 to $2,425 on TrumpRx. 
• GSK’s inhaler Advair Diskus 500/50, $265 to $89 on TrumpRx.
• Merck’s diabetes medication Januvia, $330 to $100 on TrumpRx. 
• Novartis’ Multiple Sclerosis medication Mayzent, $9,987 to $1,137 on TrumpRx. 
• Sanofi’s prescription blood thinner Plavix, $756 to $16 on TrumpRx. This company will also list its insulin products on the site for $35 a month. 

“As an American company, Merck is proud to work with the Trump administration to further secure our country’s position as a world leader in biopharmaceutical innovation. Today’s agreement marks a pivotal step in ensuring Americans can access medicines they need at lower costs,” Robert M. Davis, chairman and chief executive officer, Merck, said in a statement. “For too long, global pricing imbalances have shifted the financial burden of groundbreaking research and development onto the U.S. health care system and ultimately, American patients. Merck remains committed to expanding access and improving affordability across the system.”

Similar to the rest of the medications, it’s believed that all of the ones listed above will be available in early 2026, but it’s unclear how many patients’ primary care physicians will be involved in the process. It’s also unclear if health insurance companies will be involved in pricing and planning. 

Even so, Trump and his administration remain excited about this new business deal, with the president saying a statement earlier today, “For the American people and patients, this represents the greatest victory for patient affordability in the history of American healthcare.” 

Link to original: https://www.womansworld.com/life/money/trump-announces-trumprx-drug-discount-website-with-pfizer